Article
Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
Clinical pharmacokinetics - 1 Mar 2012
van Kuilenburg André B P, Häusler Peter, Schalhorn Andreas, Tanck Michael W T, Proost Johannes H, Terborg Christoph, Behnke Detlev, Schwabe Wolfgang, Jabschinsky Kati, Maring Jan Gerard
Abstract excerpt
BACKGROUND AND OBJECTIVE: Dihydropyrimidine dehydrogenase (DPD) is the initial enzyme in the catabolism of 5-fluorouracil (5FU) and DPD deficiency is an important pharmacogenetic syndrome. So far, only very limited information is available regarding the pharmacokinetics of 5FU in patients with a (partial) DPD deficiency and no limited sampling models have been developed taking into account the non-linear...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.